Experimental pill plus keytruda takes on tough cancers
Disease control
Ongoing
This study tests an experimental oral drug called Q702 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can sh…
Phase: PHASE1, PHASE2 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC